Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline among Postpartum Women on Antiretroviral Therapy in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 1, 2016, Pages 31-37

  Hoffmann, Christopher J ^a   Cohn, Silvia ^a   Mashabela, Fildah ^b   Hoffmann, Jennifer D ^a   McIlleron, Helen ^c   Denti, Paolo ^c   Haas, David W ^d   Dooley, Kelly E ^a   Martinson, Neil A ^a,b   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; HIV drug resistance; postnatal depression; postpartum; pregnancy; virologic failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 2B6; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; EDINBURGH POSTNATAL DEPRESSION SCALE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PERINATAL DEPRESSION; PHARMACOGENETICS; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERAL INFECTION; PUERPERIUM; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; ANTIVIRAL RESISTANCE; CD4+ T LYMPHOCYTE; CYTOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PROSPECTIVE STUDIES; RNA, VIRAL; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 84983184613     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000811     Document Type: Article

References (44)

1. Johnson L. Access to antiretroviral treatment in South Africa, 2004-2011. South Afr J HIV Med. 2012;13:22-27.
2. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418.
3. Larson E, Bendavid E, Tuoane-Nkhasi M, et al. Population-level associations between antiretroviral therapy scale-up and all-cause mortality in South Africa. Int J STD AIDS. 2013;25:636-642.
4. Bendavid E, Holmes CB, Bhattacharya J, et al. HIV development assistance and adult mortality in Africa. JAMA. 2012;307:2060-2067.
5. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva, Switzerland: World Health Organization; 2014.
6. The South African Antiretroviral Treatment Guidelines; PMTCT Guidelines Revised March 2013. South African National Department of Health: Pretoria, South Africa; 2013.
7. Motsoaledi A. Health Budget Vote Speech. Department of Health SA. ed, Pretoria, South Africa: Government of South Africa; 2014.
8. Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach. Curr Opin HIV AIDS. 2013; 8:474-489.
9. Clouse K, Schwartz S, Van Rie A, et al. "What they wanted was to give birth; nothing else": barriers to retention in option B+ HIV care among postpartum women in South Africa. J Acquir Immune Defic Syndr. 2014; 67:e12-e18.
10. Ngarina M, Popenoe R, Kilewo C, et al. Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania. BMC Public Health. 2013;13:450.
11. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-Analysis. AIDS. 2012;26:2039-2052.
12. Wettstein C, Mugglin C, Egger M, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-Analysis. AIDS. 2012;26:2361-2373.
13. Kaplan R, Orrell C, Zwane E, et al. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS. 2008;22:1679-1681.
14. Tenthani L, Haas AD, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ("Option B+") in Malawi. AIDS. 2014;28:589-598.
15. Wang B, Losina E, Stark R, et al. Loss to follow-up in a community clinic in South Africa-roles of gender, pregnancy and CD4 count. S Afr Med J. 2011;101:253-257.
16. Phillips T, Thebus E, Bekker LG, et al. Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study. J Int AIDS Soc. 2014;17:19242.
17. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-786.
18. Hoffmann CJ, Fielding KL, Johnston V, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr. 2011;58:269-276.
19. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
20. Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis Coinfection. J Infect Dis. 2014;211:197-205.
21. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012;22:858-867.
22. Haas DW, Severe P, Jean Juste MA, et al. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-Au-Prince, Haiti. J Antimicrob Chemother. 2014;69:2187-2190.
23. Wensing AM, Calvez V, Gunthard HF, et al. 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22:642-650.
24. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
25. Nel A, Kagee A. The relationship between depression, anxiety and medication adherence among patients receiving antiretroviral treatment in South Africa. AIDS Care. 2013;25:948-955.
26. Collins PY, Holman AR, Freeman MC, et al. What is the relevance of mental health to HIV/AIDS care and treatment programs in developing countries? A systematic review. AIDS. 2006;20:1571-1582.
27. Clouse K, Pettifor A, Shearer K, et al. Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health. 2013;18:451-460.
28. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis. 2009;199:872-880.
29. Barth RE, van der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155-166.
30. Okonji JA, Zeh C, Weidle PJ, et al. CD4, viral load response, and adherence among antiretroviral-naive breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya. J Acquir Immune Defic Syndr. 2012;61:249-257.
31. Denison JA, Koole O, Tsui S, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015;29:361-371.
32. Fox MP, Cutsem GV, Giddy J, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60:428-437.
33. Rusine J, Asiimwe-Kateera B, van de Wijgert J, et al. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One. 2013;8:e64345.
34. Centers for Disease C, Prevention. Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep. 2013;62:148-151.
35. Barth RE, Wensing AM, Tempelman HA, et al. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-Associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008;22:2210-2212.
36. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-1597.
37. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49:1928-1935.
38. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54:1660-1669.
39. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492-1498.
40. Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14:523-531.
41. Bhana A, Rathod SD, Selohilwe O, et al. The validity of the patient health questionnaire for screening depression in chronic care patients in primary health care in South Africa. BMC Psychiatry. 2015;15:118.
42. Peltzer K, Szrek H, Ramlagan S, et al. Depression and social functioning among HIV-infected and uninfected persons in South Africa. AIDS Care. 2015;27:41-46.
43. Yeji F, Klipstein-Grobusch K, Newell ML, et al. Are social support and HIV coping strategies associated with lower depression in adults on antiretroviral treatment? Evidence from rural KwaZulu-Natal, South Africa. AIDS Care. 2014;26:1482-1489.
44. Abas M, Ali GC, Nakimuli-Mpungu E, et al. Depression in people living with HIV in sub-Saharan Africa: time to act. Trop Med Int Health. 2014; 19:1392-1396.